Market cap
$112,224 Mln
Recently Viewed
Clear All$437.80
$0.13
(0.03%)
As on 23-Apr-2026 10:40EDT
Market cap
$112,224 Mln
Revenue (TTM)
$12,075 Mln
P/E Ratio
28.8
P/B Ratio
5.9
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$3,953 Mln
ROE
0.2 %
ROCE
19.4 %
Industry P/E
--
EV/EBITDA
21.8
Debt to Equity
0.2
Book Value
$72.9
EPS
$15.4
Face value
--
Shares outstanding
254,359,735
CFO
$16,606.24 Mln
EBITDA
$15,617.12 Mln
Net Profit
$14,123.87 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vertex Pharmaceuticals (VRTX)
| -3.4 | -3.6 | -6.3 | -10.7 | 9.8 | 15.2 | 17.6 |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P 100
| 1.3 | 10.1 | 2.5 | 37.6 | 22.9 | 13.3 | 14.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Vertex Pharmaceuticals (VRTX)
| 12.6 | -1.0 | 40.9 | 31.5 | -7.1 | 7.9 | 32.1 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vertex Pharmaceuticals (VRTX)
|
437.8 | 112,223.5 | 12,074.6 | 3,953.2 | 38.4 | 22.5 | 28.8 | 5.9 |
| 312.6 | 41,317.3 | 3,713.9 | 313.8 | 11.2 | 73.3 | 133.5 | 52.4 | |
| 143.1 | 31,186.3 | 606.4 | -1,276.8 | -196.7 | -249.3 | -- | 42.2 | |
| 74.6 | 12,506.7 | 944.0 | -381.0 | -31.6 | -70.7 | -- | 25.6 | |
| 161.3 | 29,945.3 | 16,310.0 | 1,360.0 | 14.2 | 21.6 | 21.9 | 4.4 | |
| 54.7 | 21,304.7 | 1,944.0 | -2,822.0 | -142.4 | -28.9 | -- | 2.5 | |
| 131.4 | 13,402.6 | 2,860.5 | 478.6 | 24.1 | 16.4 | 28.5 | 4.1 | |
| 754.6 | 79,350.1 | 14,342.9 | 4,504.9 | 36.8 | 14.9 | 18.1 | 2.5 | |
| 23.3 | 19,500.6 | 0.0 | -1,079.6 | -- | -206.1 | -- | 29.6 | |
| 571.8 | 25,787.3 | 3,182.7 | 1,334.7 | 54.1 | 19.7 | 21.1 | 3.6 |
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic... fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Read more
Executive Chairman
Dr. Jeffrey Marc Leiden M.D., Ph.D.
Executive Chairman
Dr. Jeffrey Marc Leiden M.D., Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Vertex Pharmaceuticals Incorporated (VRTX) is $437.80 (NASDAQ) as of 23-Apr-2026 10:40 EDT. Vertex Pharmaceuticals Incorporated (VRTX) has given a return of 9.76% in the last 3 years.
The P/E ratio of Vertex Pharmaceuticals Incorporated (VRTX) is 28.82 times as on 17-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
29.37
|
6.22
|
|
2024
|
-195.86
|
6.39
|
|
2023
|
29.33
|
6.04
|
|
2022
|
22.63
|
5.40
|
|
2021
|
24.10
|
5.59
|
The 52-week high and low of Vertex Pharmaceuticals Incorporated (VRTX) are Rs 510.77 and Rs 362.50 as of 23-Apr-2026.
Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalisation of $ 112,224 Mln as on 17-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Vertex Pharmaceuticals Incorporated (VRTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.